智通财经网·2025-08-01 07:59Core Viewpoint - The company, Borui Pharmaceutical, has signed a collaboration research agreement with China Resources Sanjiu for the development, registration, production, and commercialization of BGM0504 injection in mainland China [1] Group 1: Collaboration Agreement - Borui Pharmaceutical and its subsidiaries have granted China Resources Sanjiu exclusive collaboration development and commercialization licenses for BGM0504 injection [1] - The agreement allows for a sublicensable exclusive collaboration development implementation license and a sublicensable exclusive commercialization implementation license [1] Group 2: Product Details - BGM0504 injection is a dual agonist of GLP-1 and GIP, classified as a first-class innovative chemical drug that has not yet been marketed domestically or internationally [1] - The injection aims to control blood sugar, promote weight loss, and treat non-alcoholic steatohepatitis (NASH), showcasing potential for various metabolic disease treatments [1] Group 3: Development Status - BGM0504 injection is currently in the research phase and requires completion of Phase III clinical trials before it can be reviewed and approved by the National Medical Products Administration for production and market launch [1]